{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:08:34Z","timestamp":1790024914318,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiology Case Reports"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.radcr.2025.01.021","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:46:48Z","timestamp":1738198008000},"page":"2093-2100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8995-1058","authenticated-orcid":false,"given":"Ibrahim","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Fahim","family":"Faiyaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Imran","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmuda","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.radcr.2025.01.021_bib0001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.radcr.2025.01.021_bib0002","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.xkme.2019.11.009","article-title":"Advances in autosomal dominant polycystic kidney disease: a clinical review","volume":"2","author":"Nobakht","year":"2020","journal-title":"Kidney Med"},{"issue":"4","key":"10.1016\/j.radcr.2025.01.021_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrneph.2009.13","article-title":"Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease","volume":"5","author":"Ecder","year":"2009","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.radcr.2025.01.021_bib0004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ckj\/sft031","article-title":"Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)","volume":"6","author":"Sans-Atxer","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.radcr.2025.01.021_bib0005","series-title":"Polycystic Kidney Disease","article-title":"The liver and polycystic kidney disease","author":"de","year":"2015"},{"issue":"10","key":"10.1016\/j.radcr.2025.01.021_bib0006","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with Tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.radcr.2025.01.021_bib0007","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.radcr.2025.01.021_bib0008","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.radcr.2025.01.021_bib0009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.radcr.2025.01.021_bib0010","doi-asserted-by":"crossref","first-page":"13794","DOI":"10.1038\/s41598-024-62776-8","article-title":"Improved predictions of total kidney volume growth rate in ADPKD using two-parameter least squares fitting","volume":"14","author":"Hu","year":"2024","journal-title":"Scient Rep"},{"issue":"25","key":"10.1016\/j.radcr.2025.01.021_bib0011","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.radcr.2025.01.021_bib0012","first-page":"109","article-title":"HALT PKD Investigators. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials","volume":"13","author":"Brosnahan","year":"2017","journal-title":"Curr Hypertens Rev"},{"issue":"4","key":"10.1016\/j.radcr.2025.01.021_bib0013","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2215\/CJN.00060108","article-title":"Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies","volume":"3","author":"Chapman","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.radcr.2025.01.021_bib0014","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2024.08.008","article-title":"Treatment of autosomal dominant polycystic kidney disease","author":"Jdiaa","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"10.1016\/j.radcr.2025.01.021_bib0015","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Sergeyeva O; REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.radcr.2025.01.021_bib0016","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.radcr.2025.01.021_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","article-title":"Hypertension in autosomal dominant polycystic kidney disease","volume":"17","author":"Chapman","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1016\/j.radcr.2025.01.021_bib0018","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: results from the TEMPO 3:4 Trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.radcr.2025.01.021_bib0019","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2412721","article-title":"Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network","volume":"46","author":"Wu","year":"2024","journal-title":"Renal Fail"},{"issue":"3","key":"10.1016\/j.radcr.2025.01.021_bib0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"24","key":"10.1016\/j.radcr.2025.01.021_bib0021","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.radcr.2025.01.021_bib0022","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.nefro.2022.10.002","article-title":"The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis","volume":"43","author":"Li","year":"2023","journal-title":"Nefrologia"},{"issue":"5","key":"10.1016\/j.radcr.2025.01.021_bib0023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ckj\/sft031","article-title":"Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)","volume":"6","author":"Sans-Atxer","year":"2013","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.radcr.2025.01.021_bib0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"}],"updated-by":[{"DOI":"10.1016\/j.radcr.2026.09.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["Radiology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043325000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043325000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:53:42Z","timestamp":1741600422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1930043325000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1930043325000196"],"URL":"https:\/\/doi.org\/10.1016\/j.radcr.2025.01.021","relation":{},"ISSN":["1930-0433"],"issn-type":[{"value":"1930-0433","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement","name":"articletitle","label":"Article Title"},{"value":"Radiology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radcr.2025.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of University of Washington.","name":"copyright","label":"Copyright"}]}}